Shuttle Pharmaceuticals Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$11.9M | -$7.7M | -$5.9M | -$2.3M | -$1.7M |
| Operating expenses | $11.9M | $7.7M | $5.9M | $2.3M | $1.7M |
| Cash from operations | -$9.5M | -$7.3M | -$5.6M | -$2.7M | -$300,336 |
| Capital expenditure | — | — | $19,046 | — | — |
| Free cash flow | — | — | -$5.6M | — | — |
| Impairments | $109,235 | — | — | — | — |
| Total assets | $10.5M | $2.5M | $6.0M | $8.7M | $651,641 |
| Total liabilities | $8.2M | $1.8M | $1.9M | $975,676 | $2.3M |
| Total debt | — | — | — | — | $500,000 |
Shares outstanding 5.9M · Free float 46.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.